卡铂、长春新碱、甲氨蝶呤和博来霉素（COMB）用于宫颈癌的I-II期研究。
Phase I-II study of carboplatin vincristine methotrexate and bleomycin (COMB) in carcinoma of the cervix.
作者信息
Rustin G J, Newlands E S
机构信息
Cancer Research Campaign Laboratories, Charing Cross Hospital, London, UK.
出版信息
Br J Cancer. 1988 Dec;58(6):818-9. doi: 10.1038/bjc.1988.317.
Platinum based combination chemotherapy has been associated with a high response rate in patients with cervical carcinoma. To determine whether the toxicity could be reduced but the efficacy maintained carboplatin 200 mg m-2 was substituted for cisplatin in a regimen that was repeated two weekly and also contained vincristine, methotrexate and bleomycin. Twenty-four patients with squamous cell carcinoma of the cervix of whom 17 had relapsed following radiotherapy were studied. Only 5 of the 19 evaluable patients had a partial response (26%, 95 confidence limits 45.7-6.3%) compared to 30 of 43 (70%, 84-56%) who received a cisplatin combination in a previous study (P less than 0.01) (Rustin et al., 1987). Carboplatin as given in the COMB regimen appears less effective than cisplatin containing combinations for squamous cell carcinoma of the cervix.
铂类联合化疗已被证实与宫颈癌患者的高缓解率相关。为了确定在维持疗效的同时能否降低毒性，在一个每两周重复一次且包含长春新碱、甲氨蝶呤和博来霉素的方案中，用卡铂200mg/m²替代顺铂。对24例宫颈鳞状细胞癌患者进行了研究，其中17例在放疗后复发。19例可评估患者中只有5例出现部分缓解（26%，95%置信区间45.7 - 6.3%），而在之前的一项研究中，43例接受顺铂联合化疗的患者中有30例出现部分缓解（70%，84 - 56%）（P<0.01）（拉斯汀等人，1987年）。COMB方案中使用的卡铂对于宫颈鳞状细胞癌似乎不如含顺铂的联合化疗有效。
Zotero 插件